Portola Pharma (PTLA) Stock News
NASDAQ:PTLA - Nasdaq -
PTLA Latest News, Press Relases and Analysis
Ex-Pharma Executive Avoids Prison for Tipping Pal About Merger
A former Alexion Pharmaceuticals Inc. executive avoided jail after pleading guilty to sharing information about the company’s planned purchase of another company in 2020 with a boyhood friend.
Mentions: ALXN
Alexion completes acquisition of Portola Pharma; SEC charges with FCPA violations (NASDAQ:ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN) has completed its acquisition of Portola Pharmaceuticals (NASDAQ:PTLA), through a tender offer and merger with its subsidiary, Odyssey Merger Sub Inc. (“Buyer”).
Mentions: ALXN
Company News for May 6, 2020
Companies in the news are: LITE, ITW, INCY, PTLA
Merger Arbs Are Confident Despite Whispers on Tiffany Deal
Most other prominent deals are expected to close, and arbitrage spreads have tightened sharply since mid-March.
Portola Pharmaceuticals Announces Virtual 2020 Annual Stockholder Meeting
Portola Pharmaceuticals Announces Virtual 2020 Annual Stockholder Meeting
Macy’s and Portola See Investor Activists Buy Up Stakes
Vesa Equity Investments disclosed a large investment in Macy’s stock, and plans to have talks with management and other shareholders.
U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year
Elliott wants Alexion sale (NASDAQ:ALXN)
Calling a purchase of Portola Pharmaceuticals (NASDAQ:PTLA) the "wrong direction," Elliott Advisors suggests Alexion (NASDAQ:ALXN) instead put itself on the block.Alexion, says Elliott, is tra
Mentions: ALXN
Portola Pharmaceuticals (PTLA) Reports Q1 Loss, Misses Revenue Estimates
Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of -18.92% and -26.45%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Portola Pharmaceuticals EPS misses by $0.07, misses on revenue (NASDAQ:PTLA)
Portola Pharmaceuticals (NASDAQ:PTLA): Q1 GAAP EPS of -$0.88 misses by $0.07.Revenue of $26.39M (+18.9% Y/Y) misses by $7.49M.Shares -0.22% PM.Press Release
Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
Notable earnings after Monday's close
AEE, AFG, AIMT, AMBC, AMCR, AMN, BE, BHF, CABO, CBT, CDLX, CSOD, CZR, DDOG, DIOD, DRH, EB, ECPG, ENSG, ERI, ET, ETH, EXTR, FATE, FOE, G, GDOT, GO, GSKY, GWPH, HALO, HHC, IFF, IIVI, IPAR, JCOM, KAMN, K
Stock Market Rally Gains Steam: Shopify, PayPal, Twilio, MercadoLibre, Fortinet, Chegg Soar On Earnings
The stock market rally soared on coronavirus recovery hopes, entering a power trend. PayPal and Chegg were among several big earnings winners.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Portola Pharmaceuticals, Inc. - PTLA
Alexion (ALXN) Beats on Q1 Earnings & Sales, Lowers Guidance
Alexion (ALXN) beats on earnings and sales in the first quarter of 2020 but lowers view due to the ongoing pandemic.
Alexion Stock Drops Despite Solid Earnings Because the Company Cut Guidance
Alexion reported revenue for the first quarter of 2020 of $1.4 billion, 27% higher than a year earlier, and earnings per share of $3.22. But it cut guidance for the full fiscal year, saying it now expects revenue of between $5.2 billion and $5.3 billion.
Alexion Earnings Top But Biotech Cuts 2020 Guidance
Alexion earnings easily beat first-quarter estimates, but the biotech giant trimmed full-year targets. ALXN stock was not yet active early Wednesday.
Mentions: ALXN
70 Biggest Movers From Yesterday
Gainers Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) shares jumped 130% to close at $17.85 on Tuesday after the company announced it will be acquired by Alexion Pharmaceuticals...